Recent Updates
Recently added Catalysts
AGEN Negative Sentiment Score: 20/100

Agenus Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights – AGEN

Key Takeaway: Agenus Inc. is facing a class action securities lawsuit led by Levi & Korsinsky, LLP, filed on behalf of investors adversely affected by alleged securities fraud. The complaint claims that the defendants misrepresented the effectiveness of their immuno-oncology products, botensilimab and balstilimab, leading to materially false public statements. Investors who suffered losses during the specified timeframe can contact the firm to discuss their rights and seek compensation. The deadline to request to be appointed as lead plaintiff is November 5, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • Agenus Inc. is facing a class action lawsuit for securities fraud.
  • The lawsuit alleges that the efficacy of their immuno-oncology products was overstated.
  • Investors may have incurred losses due to misleading public statements by the company.
  • The timeframe of the alleged fraud spans from January 23, 2023, to July 17, 2024.

Full Press Release Details

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team:
AGEN investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the combination therapy of their immuno-oncology products, botensilimab and balstilimab was less effective than the defendants had led investors to believe; (ii) accordingly, botensilimab and balstilimab’s clinical results, as well as their regulatory and commercial prospects, were overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Agenus during the relevant time frame, you have until November 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the Agenus class action lawsuit about?

The lawsuit involves alleged securities fraud affecting Agenus investors between January 23, 2023, and July 17, 2024.

How can Agenus investors participate in the lawsuit?

Investors can request to be appointed as lead plaintiff by November 5, 2024, without obligation.

Are there any costs to join the Agenus lawsuit?

Class members may receive compensation with no out-of-pocket costs or fees required.

What allegations are made against Agenus?

The suit alleges that Agenus misrepresented the effectiveness of its immuno-oncology products.

Who can I contact for more information about the lawsuit?

Contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or call (212) 363-7500.

Last updated: Sep 16, 2024